Flu pandemic threat leads drugmakers to look at former medicines

10/7/2005 | NYTimes.com

Drugmakers are re-examining products they developed years ago to treat influenza now that authorities are issuing warnings worldwide about a possible pandemic and are concerned about drug shortages. A previous lack of commercial interest slowed the development of some drugs that showed efficacy in lab tests, one expert said. One candidate is BioCryst Pharmaceuticals' peramivir, which was ineffective in clinical trials as an oral drug, but now is undergoing new tests as a drug given intravenously or by injection.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA